EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase II)Open Access · CC BY-NC-ND 4.0

A multicenter, randomized, open‐label, phase 2 clinical study of telitacicept in adult patients with generalized myasthenia gravis

Jian Yin iD, Mingming Zhao, Xianhao Xu, Meini Zhang, Zucai Xu, Zunbo Li, Xinyue Qin, Zhuyi Li, Chongbo Zhao iD, Hongyu Zhou, Ying Ma, Wenfeng Cao und 17 weitere

European Journal of Neurology · 2024-08 · 31 (8)

DOI: 10.1111/ene.16322 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Neurology, online erschienen am 10.05.2024. Verfasst von Jian Yin und 28 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beij…. Hauptthemen laut MEDLINE: Myasthenia Gravis. Die Arbeit wurde bisher 50-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National High Level Hospital Clinical Reaearch Funding, RemeGen Co., Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and purpose This study aimed to investigate the clinical efficacy and safety of telitacicept in patients with generalized myasthenia gravis (gMG) who tested positive for acetylcholine receptor antibodies or muscle‐specific kinase antibodies and were receiving standard‐of‐care therapy.

Methods

Patients meeting the eligibility criteria were randomly assigned to receive telitacicept subcutaneously once a week for 24 weeks in addition to standard‐of‐care treatment. The primary efficacy endpoint was the mean change in the quantitative myasthenia gravis (QMG) score from baseline to week 24. Secondary efficacy endpoints included mean change in QMG score from baseline to week 12 and gMG clinical absolute score from baseline to week 24. Additionally, safety, tolerability and pharmacodynamics were assessed.

Results

Twenty‐nine of the 41 patients screened were randomly selected and enrolled. The mean (± standard deviation [SD]) reduction in QMG score from baseline to week 24 was 7.7 (± 5.34) and 9.6 (± 4.29) in the 160 mg and 240 mg groups, respectively. At week 12, mean reductions in QMG scores for these two groups were 5.8 (± 5.85) and 9.5 (± 5.03), respectively, indicating rapid clinical improvement. Safety analysis revealed no adverse events leading to discontinuation or mortalities. All patients showed consistent reductions in serum immunoglobulin (Ig) A, IgG and IgM levels throughout the study.

Conclusion

Telitacicept demonstrated safety, good tolerability and reduced clinical severity throughout the study period. Further validation of the clinical efficacy of telitacicept in gMG will be conducted in an upcoming phase 3 clinical trial.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myasthenia GravisHumansFemaleMaleMiddle AgedAdultAgedTreatment OutcomeReceptors, Cholinergic

Stichwörter der Autor:innen

B lymphocyte stimulatorautoimmune diseaseclinical trialimmunotherapymyasthenia gravis

Substanzen

Receptors, Cholinergic

Autor:innen und Institutionen

  • Department of Neurology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
  • Department of Neurology, First Hospital of Shanxi Medical University, Taiyuan, China.
  • Department of Neurology, Affiliated Hospital of Zunyi Medical University, Zunyi, China.
  • Department of Neurology, Xi'an Gaoxin Hospital, Xi'an, China.
  • Department of Neurology, First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
  • Department of Neurology, Tangdu Hospital, Air Force Medical University of PLA (formerly known as the Fourth Military Medical University), Xi'an, China.

ORCID-Profile: Jian Yin, Chongbo Zhao, Wei Qiu

Förderung

  • National High Level Hospital Clinical Reaearch Funding
  • RemeGen Co., Ltd

Zitieren

APA

Yin, J., Zhao, M., Xu, X., Zhang, M., Xu, Z., Li, Z., Qin, X., Li, Z., Zhao, C., Zhou, H., Ma, Y., Cao, W., Wang, G., Lin, Y., Zhang, J., Zhang, X., Cai, H., Qian, W., Wang, Y., …, & Fang, J. (2024). A multicenter, randomized, open‐label, phase 2 clinical study of telitacicept in adult patients with generalized myasthenia gravis. European Journal of Neurology, 31(8). https://doi.org/10.1111/ene.16322

Vancouver

Yin J, Zhao M, Xu X, Zhang M, Xu Z, Li Z, et al. A multicenter, randomized, open‐label, phase 2 clinical study of telitacicept in adult patients with generalized myasthenia gravis. European Journal of Neurology. 2024;31(8). doi:10.1111/ene.16322

BibTeX
@article{Yin2024,
  author = {Yin, Jian and Zhao, Mingming and Xu, Xianhao and Zhang, Meini and Xu, Zucai and Li, Zunbo and Qin, Xinyue and Li, Zhuyi and Zhao, Chongbo and Zhou, Hongyu and Ma, Ying and Cao, Wenfeng and Wang, Guoping and Lin, Yongzhong and Zhang, Jizhong and Zhang, Xu and Cai, Hongbin and Qian, Weidong and Wang, Yiqi and Zhang, Xinghu and Liu, Guangzhi and Wang, Jiawei and Qiu, Wei and Min, Lianqiu and Li, Jing and Deng, Hui and Chu, Lan and Zhang, Yifan and Fang, Jianmin},
  title = {A multicenter, randomized, open‐label, phase 2 clinical study of telitacicept in adult patients with generalized myasthenia gravis},
  journal = {European Journal of Neurology},
  year = {2024},
  volume = {31},
  number = {8},
  doi = {10.1111/ene.16322}
}
Kostenlos starten →